RESUMO
Basal ganglia (BG) circuits orchestrate complex motor behaviors predominantly via inhibitory synaptic outputs. Although these inhibitory BG outputs are known to reduce the excitability of postsynaptic target neurons, precisely how this change impairs motor performance remains poorly understood. Here, we show that optogenetic photostimulation of inhibitory BG inputs from the globus pallidus induces a surge of action potentials in the ventrolateral thalamic (VL) neurons and muscle contractions during the post-inhibitory period. Reduction of the neuronal population with this post-inhibitory rebound firing by knockout of T-type Ca2+ channels or photoinhibition abolishes multiple motor responses induced by the inhibitory BG input. In a low dopamine state, the number of VL neurons showing post-inhibitory firing increases, while reducing the number of active VL neurons via photoinhibition of BG input, effectively prevents Parkinson disease (PD)-like motor symptoms. Thus, BG inhibitory input generates excitatory motor signals in the thalamus and, in excess, promotes PD-like motor abnormalities. VIDEO ABSTRACT.
Assuntos
Globo Pálido/fisiologia , Neurônios Motores/fisiologia , Inibição Neural/fisiologia , Tálamo/fisiologia , Potenciais de Ação/fisiologia , Oxirredutases do Álcool/genética , Animais , Canais de Cálcio Tipo T/genética , Canais de Cálcio Tipo T/fisiologia , Dopamina/metabolismo , Distonia/dietoterapia , Distonia/tratamento farmacológico , Distonia/fisiopatologia , Feminino , Globo Pálido/citologia , Globo Pálido/metabolismo , Levodopa/uso terapêutico , Masculino , Erros Inatos do Metabolismo/dietoterapia , Erros Inatos do Metabolismo/tratamento farmacológico , Erros Inatos do Metabolismo/fisiopatologia , Camundongos , Camundongos Knockout , Contração Muscular/fisiologia , Vias Neurais/fisiologia , Neurônios/fisiologia , Transtornos Psicomotores/dietoterapia , Transtornos Psicomotores/tratamento farmacológico , Transtornos Psicomotores/fisiopatologia , Tálamo/citologiaRESUMO
The metabolic roles of carnitine have been greatly clarified over the past 50 years, and it is now well established that carnitine is a key player in mitochondrial generation of energy and metabolism of acetyl coenzyme A. A therapeutic role for carnitine in treatment of nutritional deficiencies in infants and children was first demonstrated in 1958, and since that time it has been used to treat a number of inborn errors of metabolism. Carnitine was approved by the US Food and Drug Administration in 1985 for treatment of 'primary carnitine deficiency', and later in 1992 for treatment of 'secondary carnitine deficiency', a definition that included the majority of relevant metabolic disorders associated with low or abnormal plasma carnitine levels. Today, carnitine treatment of inborn errors of metabolism is a safe and integral part of many treatment protocols, and a growing interest in carnitine has resulted in greater recognition of many causes of carnitine depletion. Notwithstanding, there is still a lack of data from randomized clinical trials, even on the use of carnitine in inborn errors of metabolism, although ethical issues may be a contributing factor in this regard.
Assuntos
Cardiomiopatias/prevenção & controle , Carnitina/deficiência , Carnitina/uso terapêutico , Ciências da Nutrição Infantil/história , Deficiências Nutricionais/prevenção & controle , Suplementos Nutricionais , Hiperamonemia/prevenção & controle , Erros Inatos do Metabolismo/dietoterapia , Doenças Musculares/prevenção & controle , Ciências da Nutrição/história , Administração Intravenosa , Adulto , Cardiomiopatias/dietoterapia , Cardiomiopatias/história , Cardiomiopatias/fisiopatologia , Carnitina/administração & dosagem , Carnitina/efeitos adversos , Carnitina/história , Carnitina Aciltransferases/deficiência , Carnitina Aciltransferases/história , Criança , Ensaios Clínicos como Assunto , Deficiências Nutricionais/dietoterapia , Deficiências Nutricionais/história , Deficiências Nutricionais/fisiopatologia , Suplementos Nutricionais/efeitos adversos , Metabolismo Energético , História do Século XX , História do Século XXI , Humanos , Hiperamonemia/dietoterapia , Hiperamonemia/história , Hiperamonemia/fisiopatologia , Lactente , Erros Inatos do Metabolismo Lipídico/dietoterapia , Erros Inatos do Metabolismo Lipídico/tratamento farmacológico , Erros Inatos do Metabolismo Lipídico/história , Erros Inatos do Metabolismo Lipídico/fisiopatologia , Erros Inatos do Metabolismo/tratamento farmacológico , Erros Inatos do Metabolismo/história , Erros Inatos do Metabolismo/fisiopatologia , Doenças Musculares/dietoterapia , Doenças Musculares/história , Doenças Musculares/fisiopatologia , Produção de Droga sem Interesse Comercial/históriaRESUMO
BACKGROUND: In order to achieve metabolic stability, dietary treatment of inborn errors of metabolism may require restriction of protein, fat or carbohydrate. Manipulation of dietary intake potentially reduces micronutrient status, and provision of a comprehensive vitamin and mineral supplement becomes an essential adjunct to dietary treatment. AIM: To review the efficacy of a new complete vitamin and mineral supplement [Fruitivits, Vitaflo Ltd] in 14 subjects in an open prospective 26-week study. METHOD: All subjects had dietary restrictions: low protein diets (57%, n = 8), regular daytime cornstarch and overnight glucose polymer tube feeds (29%, n = 4), low fat diet (7%, n = 1) and modified Atkins diet (7%, n = 1). Plasma nutritional biochemistry, anthropometry and food frequency questionnaires were collected at week 0, 12 and 26 weeks respectively. RESULTS: Five nutritional parameters showed a significant improvement from baseline (week 0) to study end (week 26): folate (P = 0.01), vitamin E (P = 0.04), plasma selenium (P = 0.002), whole blood selenium (P = 0.04) and total vitamin D (P = 0.008). All the other nutritional markers did not significantly change. Even with regular monitoring, 37% of the product remained unused. CONCLUSIONS: Despite improvements in some nutritional markers, overall use of the vitamin and mineral supplement was less than prescribed. New methods are needed to guarantee delivery of micronutrients in children at risk of deficiencies as a result of an essential manipulation of diet in inborn disorders of metabolism.
Assuntos
Fenômenos Fisiológicos da Nutrição Infantil , Deficiências Nutricionais/prevenção & controle , Suplementos Nutricionais , Erros Inatos do Metabolismo/dietoterapia , Cooperação do Paciente , Oligoelementos/uso terapêutico , Vitaminas/uso terapêutico , Adolescente , Fenômenos Fisiológicos da Nutrição do Adolescente , Bebidas , Biomarcadores/sangue , Criança , Pré-Escolar , Deficiências Nutricionais/etiologia , Dieta com Restrição de Gorduras/efeitos adversos , Dieta Rica em Proteínas e Pobre em Carboidratos/efeitos adversos , Dieta com Restrição de Proteínas/efeitos adversos , Nutrição Enteral/efeitos adversos , Feminino , Humanos , Intubação Gastrointestinal/efeitos adversos , Masculino , Erros Inatos do Metabolismo/sangue , Erros Inatos do Metabolismo/fisiopatologia , Estado NutricionalRESUMO
BACKGROUND: SLC6A8, an X-linked gene, encodes the creatine transporter (CRTR) and its mutations lead to cerebral creatine (Cr) deficiency which results in mental retardation, speech and language delay, autistic-like behaviour and epilepsy (CRTR-D, OMIM 300352). CRTR-D represents the most frequent Cr metabolism disorder but, differently from Cr synthesis defects, that are partially reversible by oral Cr supplementation, does not respond to Cr treatment even if precociously administrated. The precursors of Cr are the non-essential amino acids Glycine (Gly) and Arginine (Arg), which have their own transporters at the brain-blood barrier level and, therefore, their supplementation appears an attractive and feasible therapeutic option aimed at stimulating Cr endogenous synthesis and, in this way, at overcoming the block of Cr transport within the brain. However, until now the effects of Arg and/or Gly supplementation on Cr brain levels and behaviour have been controversial. METHODS: In this study five Italian male patients affected by CRTR-D were supplemented with oral L-Arg at a dosage of 300 mg/kg/day divided into 3 doses, for 24-36 months. Biochemical and plasmatic amino acids examinations and thyroid hormone dosages were periodically performed. Moreover, Proton and Phosphorus Magnetic Resonance Spectroscopy (MRS) was monitored during follow-up in concurrence with neuropsychological evaluations. RESULTS: During L-Arg treatment a clinical improvement in motor skills and to a lesser extent in communication and attention was observed. In addition, all patients had a reduction in the number and frequency of epileptic seizures. Daily living skills appeared also to be positively influenced by L-Arg treatment. Moreover, Total Cr and especially PhosphoCr, evaluated by proton and phosphorus spectroscopy, showed a mild increase, although well below the normal range. CONCLUSION: This study provides information to support the effectiveness of L-Arg supplement treatment in CTRT-D patients; in fact the syndromic pattern of cognitive and linguistic deficit presented by CRTR-D patients was partially altered by L-Arg supplementation especially at a qualitative clinical level. Oral L-Arg may represent not only a protective factor towards a further cognitive decline, but can lead to the acquisition of new skills.
Assuntos
Arginina/uso terapêutico , Creatina/metabolismo , Proteínas de Membrana Transportadoras/genética , Erros Inatos do Metabolismo/genética , Erros Inatos do Metabolismo/psicologia , Testes Neuropsicológicos , Humanos , Masculino , Erros Inatos do Metabolismo/metabolismo , Erros Inatos do Metabolismo/fisiopatologia , MutaçãoRESUMO
In vivo models represent important resources for investigating the physiological mechanisms underlying endocrine and metabolic disorders, and for pre-clinical translational studies that may include the assessments of new treatments. In the study of endocrine diseases, which affect multiple organs, in vivo models provide specific advantages over in vitro models, which are limited to investigation of isolated systems. In recent years, the mouse has become the popular choice for developing such in vivo mammalian models, as it has a genome that shares â¼85% identity to that of man, and has many physiological systems that are similar to those in man. Moreover, methods have been developed to alter the expression of genes in the mouse, thereby generating models for human diseases, which may be due to loss- or gain-of-function mutations. The methods used to generate mutations in the mouse genome include: chemical mutagenesis; conventional, conditional and inducible knockout models; knockin models and transgenic models, and these strategies are often complementary. This review describes some of the different strategies that are utilised for generating mouse models. In addition, some mouse models that have been successfully generated by these methods for some human hereditary endocrine and metabolic disorders are reviewed. In particular, the mouse models generated for parathyroid disorders, which include: the multiple endocrine neoplasias; hyperparathyroidism-jaw tumour syndrome; disorders of the calcium-sensing receptor and forms of inherited hypoparathyroidism are discussed. The advances that have been made in our understanding of the mechanisms of these human diseases by investigations of these mouse models are described.
Assuntos
Doenças do Sistema Endócrino/genética , Erros Inatos do Metabolismo/genética , Animais , Quinases Ciclina-Dependentes/deficiência , Quinases Ciclina-Dependentes/genética , Modelos Animais de Doenças , Doenças do Sistema Endócrino/etiologia , Doenças do Sistema Endócrino/fisiopatologia , Feminino , Técnicas Genéticas , Humanos , Hiperparatireoidismo/genética , Hipoparatireoidismo/genética , Neoplasias Maxilomandibulares/genética , Masculino , Erros Inatos do Metabolismo/etiologia , Erros Inatos do Metabolismo/fisiopatologia , Camundongos , Camundongos Knockout , Neoplasia Endócrina Múltipla/genética , Mutagênese , Receptores de Detecção de Cálcio/genéticaRESUMO
Introduction: Long-chain polyunsaturated fatty acid (LCPUFA) can be provided by diet (fatty fish, eggs, viscera and human milk) or synthetised from essential fatty acids linoleic and α-linolenic acids through the microsomal pathway. However, endogenous LCPUFA synthesis is rather low, especially for docosahexaenoic (DHA), and seems insufficient to achieve normal DHA values in individuals devoid of preformed dietary supply. Inborn errors of metabolism (IEMs) are therefore diseases with a special risk for LCPUFA deficient status. Aim: Our aim was to evaluate LCPUFA status in 132 patients with different IEMs. Methods: We performed a cross-sectional study of plasma and erythrocyte LCPUFA composition of 63 patients with IEMs treated with protein-restricted diets compared with data from 69 patients with IEMs on protein-unrestricted diets, and 43 own reference values. Results: Erythrocyte and plasma DHA and arachidonic acid concentrations were significantly decreased in patients treated with protein-restriction compared with those on protein-unrestricted diets and with our reference values (p < 0.0001). In the protein-restricted group, 45% of patients showed decreased erythrocyte and plasma DHA values (only 7% and 10%, respectively in the protein-unrestricted group) (p < 0.0001). Erythrocyte and plasma DHA values correlated with the natural protein intake in patients on protein-restriction (r = 0.257; p = 0.045; r = 0.313; p = 0.014, respectively). Conclusion: Plasma and erythrocyte DHA concentrations are decreased in patients with IEMs treated with protein restriction. DHA concentration correlates with the patients' protein intake. Supplementation of patients with LCPUFA would have a beneficial influence on their nutritional status (AU)
Introducción: Los ácidos grasos poliinsaturados de cadena larga (LCPUFA) pueden ser suministrados por la dieta o sintetizados a partir de los ácidos grasos esenciales, linoleico y α-linolénico. La síntesis endógena de LCPUFA es escasa, especialmente la de ácido docosahe-xaenoico (DHA), e insuficiente para alcanzar los valores normales de DHA en individuos que carecen de un suministro dietético de dichos ácidos preformados. Por ello, los errores innatos del metabolismo (IEM) son enfermedades con riesgo especial de deficiencia de LCPUFAs. Objetivos: Evaluar el estado de LCPUFA en 132 pacientes con diferentes IEMs. Métodos: Estudio transversal de LCPUFA en plasma y eritrocitos de 63 pacientes con IEMs tratados con dieta restringida en proteínas comparados con 69 pacientes con IEMs con una dieta libre y 43 valores de referencia. Resultados: Las concentraciones de DHA y ácido ara-quidónico en plasma y eritrocitos se hallaron disminuidas en pacientes con restricción proteica comparados con pacientes con dieta libre y valores de referencia (p < 0,0001). El 45% de pacientes con restricción proteica mostró un descenso de DHA en plasma y eritrocitos (solo un 7% y un 10%, respectivamente en aquellos con dieta libre) (p < 0,0001). Los valores de DHA en eritrocitos y plasma correlacionaron con la ingesta de proteínas naturales en pacientes con restricción proteica (r = 0,257; p = 0,045; r = 0,313; p = 0,014, respectivamente). Conclusión: Las concentraciones de DHA en plasma y eritrocitos se hallaron descendidas en pacientes con IEMs con restricción proteica, correlacionando con la ingesta proteica de los pacientes. La suplementación de dichos pacientes con LCPUFA podría ser beneficiosa para su estado nutricional (AU)
Assuntos
Humanos , Erros Inatos do Metabolismo/fisiopatologia , Ácidos Graxos Insaturados/análise , Ácidos Docosa-Hexaenoicos/análise , Dieta com Restrição de ProteínasRESUMO
Organic acidurias or organic acidemias constitute a group of inherited disorders caused by deficient activity of specific enzymes of amino acids, carbohydrates or lipids catabolism, leading to large accumulation and excretion of one or more carboxylic (organic) acids. Affected patients usually present neurologic symptoms and abnormalities, sometimes accompanied by cardiac and skeletal muscle alterations, whose pathogenesis is poorly known. However, in recent years growing evidence has emerged indicating that mitochondrial dysfunction is directly or indirectly involved in the pathology of various organic acidemias. Mitochondrial impairment in some of these diseases are generally due to mutations in nuclear genes of the tricarboxylic acid cycle or oxidative phosphorylation, while in others it seems to result from toxic influences of the endogenous organic acids to the mitochondrion. In this minireview, we will briefly summarize the present knowledge obtained from human and animal studies showing that disruption of mitochondrial homeostasis may represent a relevant pathomechanism of tissue damage in selective organic acidemias. The discussion will focus on mitochondrial alterations found in patients affected by organic acidemias and by the deleterious effects of the accumulating organic acids on mitochondrial pathways that are crucial for ATP formation and transfer. The elucidation of the mechanisms of toxicity of these acidic compounds offers new perspectives for potential novel adjuvant therapeutic strategies in selected disorders of this group.
Assuntos
Trifosfato de Adenosina/metabolismo , Ácidos Carboxílicos/metabolismo , Homeostase/fisiologia , Erros Inatos do Metabolismo/fisiopatologia , Mitocôndrias/fisiologia , Doenças Mitocondriais/fisiopatologia , Acetil-CoA C-Aciltransferase/deficiência , Erros Inatos do Metabolismo dos Aminoácidos/fisiopatologia , Animais , Síndrome de Barth/fisiopatologia , Encefalopatias Metabólicas/fisiopatologia , Encefalopatias Metabólicas Congênitas/fisiopatologia , Glutaril-CoA Desidrogenase/deficiência , Humanos , Mitocôndrias/metabolismo , Acidemia Propiônica/fisiopatologia , Púrpura/fisiopatologiaRESUMO
OBJECTIVE: To gain insight into the pathophysiological and clinical consequences of short-chain acyl-coenzyme A dehydrogenase deficiency (SCADD). STUDY DESIGN: A retrospective study of 15 fasting and 6 fat-loading tests in 15 Dutch patients with SCADD, divided into 3 genotype groups. Metabolic and endocrinologic measurements and the biochemical characteristics of SCADD, ethylmalonic acid (EMA), and C4-carnitine were studied. RESULTS: Three patients had development of hypoglycemia during fasting; all of these had originally presented with hypoglycemia. Metabolic and endocrinologic measurements remained normal during all tests. The EMA excretion increased in response to fasting and fat loading, and plasma C4-carnitine remained stable. Test results did not differ between the 3 genotype groups. CONCLUSIONS: The metabolic profiles of the 3 patients with development of hypoglycemia resemble idiopathic ketotic hypoglycemia. Because hypoglycemia generally requires a metabolic work-up and because SCADD is relatively prevalent, SCADD may well be diagnosed coincidently, thus being causally unrelated to the hypoglycemia. If SCADD has any other pathologic consequences, the accumulation of potentially toxic metabolites such as EMA is most likely involved. However, the results of our study indicate that there is no clear pathophysiological significance, irrespective of genotype, supporting the claim that SCADD is not suited for inclusion in newborn screening programs.
Assuntos
Butiril-CoA Desidrogenase/deficiência , Erros Inatos do Metabolismo/fisiopatologia , Adolescente , Criança , Pré-Escolar , Gorduras Insaturadas na Dieta/administração & dosagem , Jejum , Feminino , Humanos , Hipoglicemia/enzimologia , Lactente , Recém-Nascido , Masculino , Triagem Neonatal , Óleos de Plantas/administração & dosagem , Estudos Retrospectivos , Óleo de GirassolRESUMO
In this article, the authors explore the breadth and depth of published research linking dietary vitamins and minerals (micronutrients) to mood. Since the 1920s, there have been many studies on individual vitamins (especially B vitamins and Vitamins C, D, and E), minerals (calcium, chromium, iron, magnesium, zinc, and selenium), and vitamin-like compounds (choline). Recent investigations with multi-ingredient formulas are especially promising. However, without a reasonable conceptual framework for understanding mechanisms by which micronutrients might influence mood, the published literature is too readily dismissed. Consequently, 4 explanatory models are presented, suggesting that mood symptoms may be expressions of inborn errors of metabolism, manifestations of deficient methylation reactions, alterations of gene expression by nutrient deficiency, and/or long-latency deficiency diseases. These models provide possible explanations for why micronutrient supplementation could ameliorate some mental symptoms.
Assuntos
Afeto/fisiologia , Micronutrientes/fisiologia , Minerais/metabolismo , Vitaminas/fisiologia , Encéfalo/fisiopatologia , Deficiências Nutricionais/fisiopatologia , Deficiências Nutricionais/psicologia , Humanos , Erros Inatos do Metabolismo/fisiopatologia , Erros Inatos do Metabolismo/psicologia , Transtornos do Humor/fisiopatologia , Transtornos do Humor/psicologiaRESUMO
BACKGROUND: Guanidinoactetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine synthesis. The authors analyzed clinical, biochemical, and molecular findings in 27 patients. METHODS: The authors collected data from questionnaires and literature reports. A score including degree of intellectual disability, epileptic seizures, and movement disorder was developed and used to classify clinical phenotype as severe, moderate, or mild. Score and biochemical data were assessed before and during treatment with oral creatine substitution alone or with additional dietary arginine restriction and ornithine supplementation. RESULTS: Intellectual disability, epileptic seizures, guanidinoacetate accumulation in body fluids, and deficiency of brain creatine were common in all 27 patients. Twelve patients had severe, 12 patients had moderate, and three patients had mild clinical phenotype. Twenty-one of 27 (78%) patients had severe intellectual disability (estimated IQ 20 to 34). There was no obvious correlation between severity of the clinical phenotype, guanidinoacetate accumulation in body fluids, and GAMT mutations. Treatment resulted in almost normalized cerebral creatine levels, reduced guanidinoacetate accumulation, and in improvement of epilepsy and movement disorder, whereas the degree of intellectual disability remained unchanged. CONCLUSION: Guanidinoactetate methyltransferase deficiency should be considered in patients with unexplained intellectual disability, and urinary guanidinoacetate should be determined as an initial diagnostic approach.
Assuntos
Creatina/metabolismo , Glicina/análogos & derivados , Guanidinoacetato N-Metiltransferase/deficiência , Erros Inatos do Metabolismo/fisiopatologia , Adolescente , Adulto , Criança , Epilepsia/etiologia , Feminino , Glicina/metabolismo , Humanos , Masculino , Transtornos dos Movimentos/etiologiaRESUMO
Although inborn errors of metabolism are rarely found to be the cause of epilepsy, seizures are a frequent symptom in metabolic disorders. In a few of these, epilepsy responds to specific treatment by diet or supplementation. However, in most, no such treatment is available and conventional antiepileptic drugs must be used, often with no great success. However, because uncontrolled epilepsy will hamper development and may even lead to further cerebral damage, treatment is necessary. Seizure types are rarely specific for a particular metabolic disorder, nor are EEG findings. Other symptoms and findings must be taken into account in order to achieve a diagnosis and, in some cases, specific management. We review the main characteristics of epilepsy due to inborn errors of energy metabolism, to disturbed neuronal function due to accumulation of storage products, to toxic effects and to disturbed neurotransmitter systems. We also discuss vitamin-responsive epilepsies and a number of other metabolic disorders focusing on possible pathogenetic mechanisms and their implication for diagnosis and treatment.
Assuntos
Epilepsia/etiologia , Erros Inatos do Metabolismo/complicações , Convulsões/etiologia , Anticonvulsivantes/uso terapêutico , Eletroencefalografia , Epilepsia/terapia , Humanos , Erros Inatos do Metabolismo/fisiopatologia , Convulsões/terapiaRESUMO
BACKGROUND: The progressive ataxias are a diverse group of neurologic diseases that share features of degeneration of the cerebellum and its inflow/outflow pathways but differ in etiology, course, and associated noncerebellar system involvement. Some will have treatable causes, but for most, the pathophysiology is incompletely known. REVIEW SUMMARY: Treatment strategies will include (1) definitive therapy when available, (2) symptomatic treatment and prevention of complications, and (3) rehabilitation and support resources. The physician will have to decide whether to introduce or approve the use of therapies based on as yet-unproven mechanisms or the use of complementary medicine approaches. CONCLUSIONS: There are as yet no drugs that have been approved by the Food and Drug Administration for the treatment of the progressive ataxias and relatively few disease-modifying therapies, but symptomatic and rehabilitation interventions can greatly improve the quality of life of individuals with these disabling neurodegenerative disorders.
Assuntos
Ataxia/fisiopatologia , Ataxia/terapia , Cerebelo/fisiopatologia , Ataxia/diagnóstico , Ataxia/patologia , Ciclo Celular/fisiologia , Cerebelo/patologia , Terapias Complementares , Humanos , Canais Iônicos/fisiologia , Erros Inatos do Metabolismo/genética , Erros Inatos do Metabolismo/fisiopatologia , Erros Inatos do Metabolismo/terapia , Mitocôndrias/metabolismo , Doenças do Sistema Nervoso/diagnóstico , Doenças do Sistema Nervoso/patologia , Doenças do Sistema Nervoso/fisiopatologia , Doenças do Sistema Nervoso/terapia , Expansão das Repetições de TrinucleotídeosRESUMO
OBJECTIVES: This review focuses on the dietary treatment of four neuropediatric disorders: 1) X-linked adrenoleukodystrophy (X-ALD); 2) attention deficit disorders (ADD); 3) refractory epilepsy; and 4) inborn errors of metabolism. DEVELOPMENT: The use of Lorenzo's oil in the treatment of X-ALD has been controversial since no clear efficacy has been demonstrated because of a lack of controlled studies. Although this treatment normalizes the levels of very-long chain fatty acids in children with the cerebral form of X-ALD, the neurological symptoms persist or progress. The dietary treatment of ADD with or without hyperactivity consists of elimination diets such as the Feingold diet and megavitamins. Although the results of several controlled studies are contradictory, there is no scientific evidence that sugar, artificial food colorings or sweeteners are responsible for behavior or learning problems in children. The ketogenic diet has been effective for the control of refractory epilepsy such as infantile spasms and myoclonic seizures. Important side effects include gastrointestinal complaints, metabolic complications, poor growth and nutrition, liver abnormalities and renal calculi. The early identification and treatment of inborn errors of metabolism require prompt diagnosis and correction of metabolic abnormalities. Restriction of protein and fats may be necessary in certain neurometabolic disorders. A variety of special formulas is available to meet the nutritional requirements and avoid offending substances in neurometabolic patients. CONCLUSIONS: Dietary treatment plays an important role in the management of certain neuropediatric disorders, such as the use of special formulas in inborn errors of metabolism and the ketogenic diet in refractory epilepsy. The efficacy of Lorenzo's oil in the cerebral form of X-ALD and of the elimination of artificial food colorings and sweeteners in ADD remain to be proved.
Assuntos
Adrenoleucodistrofia/terapia , Transtorno do Deficit de Atenção com Hiperatividade/terapia , Dieta , Epilepsia/terapia , Erros Inatos do Metabolismo/terapia , Adrenoleucodistrofia/fisiopatologia , Transtorno do Deficit de Atenção com Hiperatividade/fisiopatologia , Criança , Combinação de Medicamentos , Epilepsia/fisiopatologia , Ácidos Erúcicos/uso terapêutico , Humanos , Erros Inatos do Metabolismo/fisiopatologia , Trioleína/uso terapêuticoRESUMO
A critical analysis of the literature of mitochondrial disorders reveals that genetic diseases of oxidative phosphorylation are often associated with impaired beta-oxidation, and vice versa, and preferentially affect brain, retina, heart and skeletal muscle, tissues which depend on docosahexaenoic (22:6n-3)-containing phospholipids for functionality. Evidence suggests that an increased NADH/NAD(+) ratio generated by reduced flux through the respiratory chain inhibits beta-oxidation, producing secondary carnitine deficiency while increasing reactive oxygen species and depleting alpha-tocopherol (alpha-TOC). These events result in impairment of the recently elucidated mitochondrial pathway for synthesis of 22:6n-3-containing phospholipids, since carnitine and alpha-TOC are involved in their biosynthesis. Therapeutic supplementation with 22:6n-3 and alpha-TOC is suggested.
Assuntos
Carnitina/deficiência , Ácidos Docosa-Hexaenoicos/metabolismo , Erros Inatos do Metabolismo/fisiopatologia , Fosforilação Oxidativa , Animais , Modelos Animais de Doenças , Ácidos Docosa-Hexaenoicos/uso terapêutico , Humanos , Erros Inatos do Metabolismo/dietoterapia , Camundongos , Camundongos Knockout , Mitocôndrias/genética , Mitocôndrias/metabolismo , Encefalomiopatias Mitocondriais/dietoterapia , Encefalomiopatias Mitocondriais/fisiopatologia , Lipofuscinoses Ceroides Neuronais/dietoterapia , Lipofuscinoses Ceroides Neuronais/fisiopatologia , Oxirredução , Fosfolipídeos/biossíntese , Vitamina E/metabolismo , Vitamina E/uso terapêuticoRESUMO
An elevated plasma homocysteine level may result from various environmental and genetic factors. Herediatary causes of severe hyperhomo-cysteinaemia are very rare and usually lead to disease in childhood or adolescence. Common pathology consists of early atherosclerotic vascular changes, arterioocclusive complications and venous thrombosis. Mildly elevated genetically determined plasma homocysteine levels are observed in 5% of the general population. In the last two decades research has shown mild hyperhomocysteinaemia to be linked to an increased risk of premature atherosclerosis, pregnancies complicated by neural tube defects and early pregnancy loss, and venous thrombosis. Homozygosity for thermolabile MTHFR deficiency has been identified as one important genetic factor, which expression is modified by dietary folate intake. Although mild hyperhomocysteinaemia can easily be treated by vitamin supplementation the beneficial effects of such treatment remains to be shown.
Assuntos
Homocisteína/sangue , Homocistinúria/fisiopatologia , Erros Inatos do Metabolismo/sangue , Oxirredutases/deficiência , 5,10-Metilenotetra-Hidrofolato Redutase (FADH2) , Arteriosclerose/epidemiologia , Arteriosclerose/etiologia , Feminino , Homocistinúria/sangue , Homocistinúria/tratamento farmacológico , Homocistinúria/genética , Homozigoto , Humanos , Liases/deficiência , Erros Inatos do Metabolismo/etiologia , Erros Inatos do Metabolismo/genética , Erros Inatos do Metabolismo/fisiopatologia , Metilenotetra-Hidrofolato Redutase (NADPH2) , Defeitos do Tubo Neural/epidemiologia , Defeitos do Tubo Neural/etiologia , Gravidez , Complicações na Gravidez/epidemiologia , Complicações na Gravidez/etiologia , Tromboflebite/epidemiologia , Tromboflebite/etiologiaRESUMO
The role of adrenal steroid hormones in hypertension has, until recently, focused on disorders of secretion. We describe a new form of mineralocorticoid hypertension which arises from impaired metabolism of physiological glucocorticoid. 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) is responsible for the inactivation of cortisol to cortisone. Congenital absence of this enzyme (the syndrome of apparent mineralocorticoid excess) results in cortisol acting as a potent mineralocorticoid. Furthermore, inhibition of this enzyme by glycyrrhizic and glycyrrhetinic acids also accounts for the mineralocorticoid excess states seen following licorice and carbenoxolone ingestion. Whilst impaired 11 beta-HSD activity has been shown in patients with "essential" hypertension, the significance of this finding remains unknown. These clinical studies, however, have uncovered a novel physiological mechanism, whereby the mineralocorticoid receptor (which in vitro has an equal affinity for cortisol and aldosterone) is protected from cortisol excess by the action of 11 beta-HSD. Thus 11 beta-HSD plays a crucial role in determining the in vivo specificity for this receptor.
Assuntos
Cortisona/metabolismo , Hidrocortisona/metabolismo , Hipertensão/etiologia , 11-beta-Hidroxiesteroide Desidrogenases , Animais , Carbenoxolona/farmacologia , Glycyrrhiza , Humanos , Hidroxiesteroide Desidrogenases/deficiência , Hidroxiesteroide Desidrogenases/metabolismo , Hipertensão/metabolismo , Erros Inatos do Metabolismo/metabolismo , Erros Inatos do Metabolismo/fisiopatologia , Mineralocorticoides/metabolismo , Plantas Medicinais , Receptores de Mineralocorticoides/metabolismoRESUMO
Carnitine has a fundamental biological role as a long-chain fatty acid carrier across the mitochondrial membrane and in ketone body formation. Although the body normally synthesizes carnitine, in certain circumstances such as total parenteral nutrition and haemodialysis a dietary supplement may be needed to maintain adequate levels. Several considerations suggest that carnitine is a truly essential nutrient in infancy and in other situations where the energy requirement is particularly high, e.g. pregnancy and breast feeding. There are, for example, congenital deficit syndromes due to enzymatic inadequacies. There is also the possible role of carnitine in serious metabolic disorders such as organic acidaemias and, above all, it has multiple physiological functions in major metabolic pathways which are essential for development and growth.
Assuntos
Carnitina/metabolismo , Animais , Carnitina/deficiência , Carnitina/uso terapêutico , Feminino , Humanos , Lactente , Recém-Nascido , Rim/metabolismo , Fígado/metabolismo , Erros Inatos do Metabolismo/fisiopatologia , Leite Humano/química , Necessidades Nutricionais , Gravidez , RatosRESUMO
Three family members are reported with functional symptoms considered to be caused by intracellular deficiency of thiamin. Persistence of desaturation of erythrocyte transketolase in the face of megadose thiamin hydrochloride (THCl), accompanied by a balanced multivitamin and mineral formula, suggested a familial thiamin dependency state. Each of three individuals responded clinically to the administration of thiamin tetrahydrofurfuryl disulfide (TTFD), and erythrocyte transketolase (TKA) became fully saturated with thiamin pyrophosphate (TPP). Dysautonomic symptoms observed are compared with those seen in classical beriberi, the nutritional prototype for dysautonomia, and changes in blood pressure are described which support this premise. Although there is no proof from the laboratory, it is hypothesized that the biochemical lesion might be due either to malabsorption of thiamin or its inadequate phosphorylation.